Neutrophil Extracellular Trap Components Associate with Infarct Size, Ventricular Function, and Clinical Outcome in STEMI

Figures

• 

  Figure 1. Temporal profiles of NET markers in the total population (n = 259 before PCI, n = 258 after PCI, n = 251/254 for dsDNA/MPO-DNA on day 1, and n = 258 at 4 months). Data are presented as median values with 25th and 75th percentiles. dsDNA: double-stranded deoxyribonucleic acid. MPO-DNA: myeloperoxidase-deoxyribonucleic acid. PCI: percutaneous coronary intervention. Friedman's test, Wilcoxon's signed rank test.

• 

  Figure 2. Indices of myocardial infarct size (a, b, c, d, e) and left ventricular remodeling (f, g, h) evaluated by CMR according to circulating levels of dsDNA measured on day 1. (a) n = 218, (b) n = 192, (c) n = 219, (d) n = 231, (e) n = 185, (f) n = 223, (g) n = 232, and (h) n = 212. LVEF: left ventricular ejection fraction. LVEDVi: left ventricular end-diastolic volume index. dsDNA: double-stranded deoxyribonucleic acid. dsDNA ≤ median: ≤366 ng/ml. dsDNA > median: >367 ng/ml. Chi-square test in (a), Mann-Whitney's test in (b)–(h).

• 

  Figure 3. Adverse clinical events during 12-month follow-up according to dsDNA levels measured on day 1 (n = 251). dsDNA: double-stranded deoxyribonucleic acid. MPO-DNA: myeloperoxidase-deoxyribonucleic acid. PCI: percutaneous coronary intervention. dsDNA ≤ median: ≤366 ng/ml. dsDNA > median: >366 ng/ml. Kaplan-Meyer's survival plot.